Fast Facts: Myeloproliferative Neoplasms

Cover
Title Page
Copyright
Contents
List of abbreviations
Introduction

1. Pathogenesis and etiology
Genetic basis
Clonal hematopoiesis of indeterminate potential (CHIP)
Inflammation
Other environmental factors

2. Epidemiology
Incidence
Prevalence
Survival
Risk factors

3. Diagnosis and disease burden
Clinical presentation
Diagnosis
Diagnosis of essential thrombocythemia
Diagnosis of polycythemia vera
Diagnosis of primary myelofibrosis
Disease burden
Risk stratification

4. Management of essential thrombocythemia
Aims of treatment
Stratification of treatment according to risk
First-line treatment
Second-line treatment
Management of extreme thrombocytosis
Recognizing treatment failure

5. Management of polycythemia vera
Aims of treatment
Current treatment options
Stratification of treatment according to risk
Phlebotomy
Antiplatelet therapy
Cytoreductive therapy
Janus kinase inhibitors
Managing the risk of transformation to myelofibrosis/blast phase
Criteria for treatment response

6. Management of myelofibrosis
Aims of treatment
Risk stratification
Therapeutic options
Janus kinase inhibitors
Stem cell transplantation
Supportive therapy
Treatment of blast phase myelofibrosis
Monitoring treatment

7. New treatments for myeloproliferative neoplasms
JAK inhibitors
Ropeginterferon
Other therapeutic targets
Erythropoiesis inhibitor blockers
Combination therapy

8. Management of specific situations
MPNs in women: influence of sex on phenotype
MPNs in children
Splanchnic vein thrombosis
Elective surgery

9. Management of myeloproliferative neoplasm blast phase
Diagnosis
Treatment
Useful resources
Index